Curasight Feed

	Est. tid*
2025-11-27	08:30	Kvartalsrapport 2025-Q3
2025-08-28	08:30	Kvartalsrapport 2025-Q2
2025-05-28	N/A	Årsstämma
2025-04-25	-	Kvartalsrapport 2025-Q1
2025-04-23	-	Extra Bolagsstämma 2025
2025-04-11	-	X-dag ordinarie utdelning CURAS 0.00 DKK
2025-02-27	-	Bokslutskommuniké 2024
2024-11-21	-	Kvartalsrapport 2024-Q3
2024-08-22	-	Kvartalsrapport 2024-Q2
2024-07-02	-	Extra Bolagsstämma 2024
2024-05-23	-	Kvartalsrapport 2024-Q1
2024-03-22	-	X-dag ordinarie utdelning CURAS 0.00 DKK
2024-03-21	-	Årsstämma
2024-02-22	-	Bokslutskommuniké 2023
2023-11-23	-	Kvartalsrapport 2023-Q3
2023-08-24	-	Kvartalsrapport 2023-Q2
2023-05-25	-	Kvartalsrapport 2023-Q1
2023-03-31	-	X-dag ordinarie utdelning CURAS 0.00 DKK
2023-03-30	-	Årsstämma
2023-02-23	-	Bokslutskommuniké 2022
2022-11-24	-	Kvartalsrapport 2022-Q3
2022-08-25	-	Kvartalsrapport 2022-Q2
2022-05-24	-	Kvartalsrapport 2022-Q1
2022-04-27	-	Årsstämma
2022-03-25	-	X-dag ordinarie utdelning CURAS 0.00 DKK
2022-02-24	-	Bokslutskommuniké 2021
2021-11-25	-	Kvartalsrapport 2021-Q3
2021-08-24	-	Kvartalsrapport 2021-Q2
2021-06-01	-	Extra Bolagsstämma 2021
2021-05-20	-	Kvartalsrapport 2021-Q1
2021-03-26	-	X-dag ordinarie utdelning CURAS 0.00 DKK
2021-03-25	-	Årsstämma
2021-02-24	-	Bokslutskommuniké 2020
2020-11-30	-	Kvartalsrapport 2020-Q3

Land	Danmark
Lista	Spotlight DK
Sektor	Hälsovård
Industri	Medicinteknik

2025-05-02 07:30:53 Curasight: THE SUBSCRIPTION PERIOD IN CURASIGHT'S RIGHTS ISSUE OF SHARES BEGINS TODAY 2,27 DKK | -9,92% | 0,20 MDKK

2025-04-30 12:17:43 Curasight to present at HC Andersen Capital 2,94 DKK | +2,40% | 0,11 MDKK

2025-04-29 22:22:09 Curasight A/S publishes disclosure document regarding rights issue 2,94 DKK | +2,40% | 0,11 MDKK

2025-04-25 08:47:08 Curasight: Annual Report for the fiscal year 2024 3,33 DKK | +21,09% | 0,16 MDKK

2025-04-25 08:25:07 Curasight: Interim report Q1 2025 3,33 DKK | +21,09% | 0,16 MDKK

2025-04-24 08:30:33 Curasight: CURASIGHT A/S ANNOUNCES FINAL TERMS OF RIGHTS ISSUE 2,75 DKK | -14,46% | 0,20 MDKK

2025-04-23 11:38:15 Resolutions of the Extraordinary General Meeting of Curasight A/S on 23 April 2025 3,22 DKK | +4,09% | 0,07 MDKK

2025-04-08 20:42:48 Notice of Extraordinary General Meeting of Curasight A/S 3,53 DKK | -12,29% | 0,05 MDKK

2025-04-04 17:14:00 Curasight A/S resolves on its intention to carry out a rights issue of shares of approximately DKK 100 million 4,23 DKK | -6,60% | 0,05 MDKK

2025-03-26 07:00:00 Curasight announces new date of the Annual General Meeting and an updated financial calendar 2025 4,58 DKK | -4,09% | 0,01 MDKK

2025-02-27 07:00:00 Curasight: Year-end report Q4 2024

2025-02-05 09:24:50 Curasight announces an updated financial calendar 2025 5,16 DKK | -7,04% | 0,00 MDKK

2024-12-10 19:05:17 Participation in warrant exercise by Curasight management 6,32 DKK | +7,84% | 0,09 MDKK

2024-12-10 07:22:00 Curasight A/S announces outcome of warrant exercise 5,86 DKK | -6,85% | 0,42 MDKK

2024-12-02 08:10:00 Curasight: SEB maintain valuation range midpoint at DKK 54 per share 6,49 DKK | +1,35% | 0,45 MDKK

2024-12-02 07:00:00 Curasight: The last day of trading in warrants of series TO2 is on the 3[rd] of December 2024 6,49 DKK | +1,35% | 0,45 MDKK

2024-11-22 08:25:06 Curasight and Curium sign global radioisotope supply agreement for uTREAT[®] 6,26 DKK | -5,22% | 0,04 MDKK

2024-11-21 07:55:00 Curasight: The exercise period for warrants of series TO2 commences today 6,60 DKK | -3,36% | 0,10 MDKK

2024-11-21 07:00:00 Curasight: Interim report Q3 2024 6,60 DKK | -3,36% | 0,10 MDKK

2024-11-20 08:10:00 Curasight: The exercise price for warrants of series TO2 has been set to DKK 11.50 per new share 6,83 DKK | -6,30% | 0,11 MDKK

2024-11-14 07:00:00 Curasight to present at HC Andersen Capital, BioStock Life Science Summit 2024, and Økonomisk Ugebrev Investor Conference 6,60 DKK | -0,43% | 0,18 MDKK

2024-11-13 07:05:00 Curasight announces international patent application for uTREAT® to broaden IP protection 6,63 DKK | -1,28% | 0,02 MDKK

2024-11-11 07:00:00 Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025 6,35 DKK | +5,74% | 0,08 MDKK

2024-11-08 10:42:58 Curasight to present at Dansk Aktionærforening InvestorDagen 6,00 DKK | -0,95% | 0,03 MDKK

2024-11-07 07:00:00 Curasight: Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer 6,06 DKK | -4,52% | 0,04 MDKK

2024-10-11 13:19:10 Curasight A/S announces last day of trading in BTU and first day of trading in warrant series TO2 and TO3 6,32 DKK | 0,00% | 0,01 MDKK

2024-10-03 08:41:29 Curasight A/S rights issue heavily oversubscribed 6,32 DKK | +3,29% | 0,15 MDKK

2024-09-16 08:50:00 Commencement of subscription period in Curasight's preferential rights issue 5,56 DKK | -3,68% | 0,06 MDKK

2024-09-12 12:22:24 Curasight A/S publishes prospectus due to upcoming rights issue 5,74 DKK | -6,10% | 0,24 MDKK

2024-09-04 09:25:00 Curasight: The Board of Directors resolves on a directed issue of units and preferential rights issue of units 6,32 DKK | -6,38% | 0,04 MDKK

2024-08-22 07:00:00 Curasight: Interim report Q2 2024 6,83 DKK | -0,42% | 0,00 MDKK

2024-07-30 10:39:16 Curasight issues warrants as part of long-term incentive program 6,43 DKK | +3,70% | 0,02 MDKK

2024-07-02 14:11:38 Resolutions of the Extraordinary General Meeting of Curasight A/S on 2 July 2024 6,89 DKK | -2,04% | 0,06 MDKK

2024-07-01 11:53:10 Curasight: Directed issues registered at the Danish Business Authority 7,03 DKK | -2,00% | 0,13 MDKK

2024-06-22 11:22:54 Curasight to present at HC Andersen Capital

2024-06-17 16:05:55 Curasight: Notice of Extraordinary General Meeting 7,90 DKK | -14,06% | 0,20 MDKK

2024-06-14 17:22:12 Curasight A/S resolves on directed issues and a loan facility 9,19 DKK | +6,67% | 0,38 MDKK

2024-06-12 07:11:00 Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer 7,46 DKK | +19,82% | 0,25 MDKK

2024-05-23 07:00:00 Curasight: Interim report Q1 2024 5,91 DKK | 0,00% | 0,00 MDKK

2024-04-16 20:39:38 Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients 5,83 DKK | -1,93% | 0,10 MDKK

2024-04-12 11:58:04 Curasight announces change in the Board of Directors 5,74 DKK | +3,09% | 0,07 MDKK

2024-03-21 12:30:31 Resolutions of the Annual General Meeting 2024 of Curasight A/S 6,26 DKK | -6,03% | 0,13 MDKK

2024-03-11 21:53:10 Curasight not to proceed with rights issue; evaluating alternative financing opportunities 6,12 DKK | -28,28%

2024-03-06 11:26:47 Curasight: Notice of Annual General Meeting 2024 8,73 DKK | +2,36%

2024-02-23 08:35:35 The subscription period in Curasight's rights issue begins today 9,19 DKK | -1,23% | 0,59 MDKK

2024-02-22 12:47:45 Curasight publishes information memorandum in connection with forthcoming rights issue 9,30 DKK | +1,25% | 0,17 MDKK

2024-02-22 08:46:13 Curasight: Annual Report for the fiscal year 2023 9,30 DKK | +1,25% | 0,17 MDKK

2024-02-22 07:00:00 Curasight: Year-end report October - December 2023 9,30 DKK | +1,25% | 0,17 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Curasight

Kalender

Beskrivning

Curasight

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden